Scintica Cuts Through the Instrument Clutter to Connect Preclinical Researchers with the Right Imaging Technology

A researcher designing a study on tumor response to therapy faces a deceptively difficult question before any experiment begins: which imaging modality will actually produce the data needed to answer the hypothesis? The options span high-frequency ultrasound, MRI, DEXA, optical imaging across multiple spectral windows, PET/CT, PET/MR, SPECT, photoacoustic, and intravital microscopy. Each technology carries distinct strengths, limitations, throughput characteristics, and cost structures. Each vendor presents its own platform as the obvious choice. For scientists trained in biology, pharmacology, or oncology rather than imaging physics, navigating that landscape consumes time that should be spent on research.

Scintica was founded to eliminate that friction. The company operates as a scientific instrumentation partner for the preclinical research community, supplying imaging systems, microscopy platforms, lab equipment, physiology tools, surgical instruments, and biofabrication technology to investigators across medical schools, hospitals, pharmaceutical companies, and contract research organizations. Rather than functioning as a transactional distributor, Scintica positions itself as an advisory layer a team of scientists who help researchers identify the instrument that fits their study design, budget, and long-term research trajectory.

With more than 15 manufacturing partners, 70+ educational webinars, a scientific team spanning imaging, pharmacology, biology, chemistry, neurology, oncology, cardiology, and nanotechnology, and a presence across five continents, the company has built a model that connects discovery-focused researchers with the tools that make discovery possible. In 2025, as preclinical imaging grows more sophisticated and translational research demands greater rigor, that connective role has become more valuable than ever.

Advisory Expertise as the Core Differentiator

Scintica's most significant advantage is the scientific depth of its team. Product managers and applications specialists hold advanced degrees across disciplines directly relevant to preclinical research, allowing them to engage with investigators on study design, image acquisition parameters, and data analysis rather than simply quoting specifications. For a researcher evaluating whether PET/CT or optical imaging better suits a longitudinal oncology study, that conversation matters more than a product brochure. The advisory model reduces the risk of capital misallocation an important consideration when imaging systems represent significant institutional investment and accelerates the path from equipment selection to publishable data.

The Multi-Modality Portfolio as a Research Enabler

Scintica curates a portfolio spanning the full range of preclinical imaging technologies, which allows researchers to match modality to hypothesis rather than adapting hypotheses to available equipment. Cardiovascular investigators can access high-frequency ultrasound and laser speckle imaging for vascular function studies. Oncology researchers can combine optical imaging with PET or MRI for tumor characterization. Neuroscience teams can leverage intravital microscopy for cellular-level observation in living systems. This breadth, assembled through partnerships with more than 15 manufacturers, means Scintica can serve as a single point of contact across multiple research programs within the same institution deepening relationships and increasing lifetime value per account.

Application Support and Training as Retention Drivers

Beyond equipment delivery, Scintica provides applications support and training that extends across the research lifecycle. Teams can request guidance when launching a new study, when repurposing existing equipment for a different application, or when onboarding new personnel. This sustained engagement transforms the vendor relationship from a one-time purchase into an ongoing partnership. For the company, training and support generate recurring touchpoints that reduce churn, surface upgrade opportunities, and position Scintica as the default resource when institutions expand their imaging capabilities.

Technical Service and Preventive Maintenance

Equipment downtime in a preclinical research setting carries direct costs: delayed experiments, disrupted grant timelines, and wasted animal cohorts. Scintica's technical service and repair team provides responsive support for equipment issues, while its preventive maintenance program offers scheduled service visits tailored to specific instruments. For research institutions operating under grant-funded timelines, this reliability translates into protected research investment. For Scintica, maintenance contracts create predictable recurring revenue and reinforce the advisory relationship established during the initial sale.

Contract Research Services as an Expansion Play

Scintica's CRO services allow researchers to execute studies within a network of partner laboratories, providing access to imaging capabilities without capital expenditure. This offering serves institutions evaluating a modality before purchase, early-stage companies without in-house imaging infrastructure, and research groups needing specialized expertise for a defined project. For Scintica, CRO engagements function as a low-friction entry point that frequently converts into equipment sales once researchers experience the technology firsthand.

Education as Demand Generation

Scintica's commitment to education expressed through 70+ webinars, published articles, and event programming functions as a demand generation engine. Researchers who learn about emerging imaging technologies through Scintica content naturally turn to Scintica when planning studies that require those technologies. This inbound model lowers customer acquisition costs while reinforcing the company's positioning as a scientific partner rather than a sales organization.

The Economics of Scientific Partnership

Scintica's growth reflects sustained demand for instrumentation expertise in an increasingly complex preclinical research environment. With a multi-modality portfolio, deep scientific expertise, and services spanning advisory support through contract research, the company has established itself as a trusted partner for institutions where imaging capability determines research output. As translational medicine continues to demand more sophisticated preclinical data, the value of a partner who understands both the science and the instrumentation compounds.

Blair Poetschke, President

"We are sorting through the clutter of information to help scientists and researchers find the right instrument for their study. Our role is to simplify the search so investigators can spend their time advancing science, not evaluating specifications."